330PD - Galectin-1 (Gal-1) expression as a prognostic factor in a homogenous cohort of glioblastoma (GB) (Gliocat study)

Date 09 September 2017
Event ESMO 2017 Congress
Session CNS tumours
Topics Central Nervous System Malignancies
Translational Research
Presenter NOELIA VilariÑo Quintela
Citation Annals of Oncology (2017) 28 (suppl_5): v109-v121. 10.1093/annonc/mdx366
Authors N. VilariÑo Quintela1, N. Martinez Bosch2, C. Balana3, F. Alameda4, A. Estival3, E. Pineda5, S. Del Barco6, M. Gil7, C. Mesia8, O. Gallego9, C. Carrato10, T. Ribalta11, N. Vidal7, N. Dela Iglesia12, O. Arpi2, J. Capellades1, N. Garcia3, J.M. Velarde13, P. Navarro14, M. Martinez-Garcia1
  • 1Medical Oncology, University Hospital del Mar, 8003 - Barcelona/ES
  • 2Molecular Mechanisms, IMIM-Hospital del Mar, Barcelona/ES
  • 3Medical Oncology, Catalan Institute of Oncology (ICO Badalona), Hospital Germans Trias i Pujol, 8916 - Badalona/ES
  • 4Pathology, University Hospital del Mar, 8003 - Barcelona/ES
  • 5Medical Oncology, Hospital Clinic y Provincial de Barcelona, Barcelona/ES
  • 6Clinical Oncology, 15Instituto Catalan de Oncologia de Girona, Girona/ES
  • 7Medical Oncology, Institut Català d'Oncologia Hospital Duran i Reynals, 08907 - Barcelona/ES
  • 8Medical Oncology, Institut Catala de Oncologia, 8907 - Barcelona/ES
  • 9Medical Oncology, Hospital de la Santa Creu i Sant Pau, 8026 - Barcelona/ES
  • 10Pathology, Hospital Universitari Germans Trias i Pujol, Fundació Institut d' Investigacions en Ciencies de la Salut Germans Trias i Pujol, Catalan Institute of Oncology Badalona, 08916 - Badalona/ES
  • 11Pathology, Hospital Clinic y Provincial de Barcelona, Barcelona/ES
  • 12Biology, Hospital Clinic y Provincial de Barcelona, Barcelona/ES
  • 13Biostatistics, Hospital Universitari Germans Trias i Pujol, Fundació Institut d' Investigacions en Ciencies de la Salut Germans Trias i Pujol, Catalan Institute of Oncology Badalona, 08916 - Badalona/ES
  • 14Molecular Mechanisms, IMIM-Hopsital del Mar, Barcelona/ES

Abstract

Background

Gal-1 is a β-galactoside binding protein that plays an important role in cancer progression and has been implicated in resistance to chemotherapy and anti-VEGF therapy. Gal-1 mediates glioma aggressiveness and its expression increases with grade and correlates with worse outcome. Our aim was to evaluate the prognostic significance of Gal-1 in a homogenous cohort of GB.

Methods

GLIOCAT is a multicenter study of newly diagnosed 432 GB patients treated with Stupp regimen. Tissue from 272 patients was used to generate a tissue microarray and Gal-1 expression in cytoplasm (C) and nucleus (N) was analyzed by immunohistochemistry. Results were evaluated by three reviewers and quantified by H-Score. Expression levels were correlated with clinical characteristics, known prognostic factors and response to anti-angiogenic treatment. Preliminary results will be presented at 2017 ASCO, abstract e13526. We will report here the final results.

Results

We defined a cut off for Gal-1 H-Score of ≥ 157 (cytoplasm, C) and ≥123 (nucleus, N). High combined Gal-1 expression significantly correlated with worse OS. No correlation was found with PFS.Table:

330PD

H-ScorenmOS (months) (range)p value
Combined H-Score Low (C 

Conclusions

Gal-1 expression represents an independent prognostic factor for GB patients treated initially with standard therapy and with other therapies at recurrence.

Clinical trial identification

Legal entity responsible for the study

Gliocat group

Funding

Marató TV3 2012

Disclosure

All authors have declared no conflicts of interest.